Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia

Neuroscience Letters

Volumn 522, Issue 2, 2012, Pages 151-155

  Spangaro, Marco ^a   Bosia, Marta ^a,b   Zanoletti, Andrea ^b   Bechi, Margherita ^a   Cocchi, Federica ^a   Pirovano, Adele ^b   Lorenzi, Cristina ^a   Bramanti, Placido ^c   Benedetti, Francesco ^a,b   Smeraldi, Enrico ^a,b   Cavallaro, Roberto ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Cognitive deficit; Excitatory amino acid transporter 2 (EAAT2); Executive functions; Glutamate uptake; Schizophrenia; Working Memory

Indexed keywords

EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; METABOTROPIC RECEPTOR 3;

ADULT; AGED; ALLELE; AMINO ACID METABOLISM; ARTICLE; COGNITION; COGNITIVE DEFECT; EXECUTIVE FUNCTION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; WORKING MEMORY;

ADOLESCENT; ADULT; COGNITION DISORDERS; FEMALE; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; POLYMORPHISM, GENETIC; PREFRONTAL CORTEX; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84863876671     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.06.030     Document Type: Article

References (35)

1. Aoyama N., Théberge J., Drost D.J., Manchanda R., Northcott S., Neufeld R.W., Menon R.S., Rajakumar N., Pavlosky W.F., Densmore M., Schaefer B., Williamson P.C. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. British Journal of Psychiatry 2011, 198:448-456.
2. Bosia M., Bechi M., Marino E., Anselmetti S., Poletti S., Cocchi F., Smeraldi E., Cavallaro R. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neuroscience Letters 2007, 417:271-274.
3. Bosia M., Anselmetti S., Pirovano A., Ermoli E., Marino E., Bramanti P., Smeraldi E., Cavallaro R. HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:81-85.
4. Bosia M., Anselmetti S., Bechi M., Lorenzi C., Pirovano A., Cocchi F., Buonocore M., Bramanti P., Smeraldi E., Cavallaro R. Effect of 5-HT1A-receptor functional polymorphism on theory of mind performances in schizophrenia. Psychiatry Research 2011, 188:187-190.
5. Bustillo J.R., Chen H., Gasparovic C., Mullins P., Caprihan A., Qualls C., Apfeldorf W., Lauriello J., Posse S. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4Tesla. Biological Psychiatry 2011, 69:19-27.
6. Callicott J.H., Mattay V.S., Bertolino A., Finn K., Coppola R., Frank J.A., Goldberg T.E., Weinberger D.R. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cerebral Cortex 1999, 9:20-26.
7. Callicott J.H., Mattay V.S., Verchinski B.A., Marenco S., Egan M.F., Weinberger D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. American Journal of Psychiatry 2003, 160:2209-2215.
8. Carter C.J. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophrenia Research 2006, 86:1-14.
9. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., Myers R.M., Bunney W.E., Akil H., Watson S.J., Jones E.G. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15653-15658.
10. Domercq M., Etxebarria E., Perez-Samartin A., Matute C. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 2005, 52:36-46.
11. Dunlop J. Glutamate-based therapeutic approaches: targeting the glutamate transport system. Current Opinion in Pharmacology 2006, 6:103-107.
12. Egan M.F., Straub R.E., Goldberg T.E., Yakub I., Callicott J.H., Hariri A.R., Mattay V.S., Bertolino A., Hyde T.M., Shannon-Weickert C., Akil M., Crook J., Vakkalanka R.K., Balkissoon R., Gibbs R.A., Kleinman J.E., Weinberger D.R. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:12604-12609.
13. Fairman W.A., Amara S.G. Functional diversity of excitatory amino acid transporters: ion channel and transport modes. American Journal of Physiology 1999, 277:481-486.
14. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research 2004, 72:41-51.
15. Haugeto O., Ullensvang K., Levy L.M., Chaudhry F.A., Honore T., Nielsen M., Lehre K.P., Danbolt N.C. Brain glutamate transporter proteins form homomultimers. Journal of Biological Chemistry 1996, 271:27715-27722.
16. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991, 148:1301-1308.
17. Kaplan G.B., Sengör N.S., Gürvit H., Genç I., Güzeliş C. A composite neural network model for perseveration and distractibility in the Wisconsin Card Sorting Test. Neural Networks 2006, 19:375-387.
18. Katagiri H., Tanaka K., Manabe T. Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. European Journal of Neuroscience 2001, 14:547-553.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
20. Konradi C., Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacology & Therapeutics 2003, 97:153-179.
21. Lauriat T.L., McInnes L.A. EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders. Molecular Psychiatry 2007, 12:1065-1078.
22. Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., Volsky D.J., Fisher P.B. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. Journal of Biological Chemistry 2008, 283:13116-13123.
23. Mallolas J., Hurtado O., Castellanos M., Blanco M., Sobrino T., Serena J., Vivancos J., Castillo J., Lizasoain I., Moro M.A., Dávalos A. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. Journal of Experimental Medicine 2006, 203:711-717.
24. Marcaggi P., Attwell D. Role of glial amino acid transporters in synaptic transmission and brain energetics. Glia 2004, 47:217-225.
25. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
26. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 1999, 33:523-533.
27. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Research: Molecular Brain Research 1998, 56:207-217.
28. Ohnuma T., Tessler S., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Research: Molecular Brain Research 2000, 85:24-31.
29. Perlstein W.M., Carter C.S., Noll D.C., Cohen J.D. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. American Journal of Psychiatry 2001, 158:1105-1113.
30. Selkirk J.V., Stiefel T.H., Stone I.M., Naeve G.S., Foster A.C., Poulsen D.J. Over-expression of the human EAAT2 glutamate transporter within neurons of mouse organotypic hippocampal slice cultures leads to increased vulnerability of CA1 pyramidal cells. European Journal of Neuroscience 2005, 21:2291-2296.
31. Silver H., Feldman P., Bilker W., Gur R.C. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. American Journal of Psychiatry 2003, 160:1809-1816.
32. Steinpreis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behavioural Brain Research 1996, 74:45-55.
33. Stratta P., Arduini L., Daneluzzo E., Rinaldi O., di Genova A., Rossi A. Relationship of good and poor Wisconsin Card Sorting Test performance to illness duration in schizophrenia: a cross-sectional analysis. Psychiatry Research 2004, 121:219-227.
34. Suzuki M., Nelson A.D., Eickstaedt J.B., Wallace K., Wright L.S., Svendsen C.N. Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex. European Journal of Neuroscience 2006, 24:645-653.
35. Wang Y., Qin Z.H. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 2010, 15:1382-1402.